Study ID (Protocol Number)
CA209-040
 
STUDY LOCATIONS*


 




*Not all study site locations may be listed - please check back soon for updated
information. For more information regarding other participating countries, please
visit clinicaltrials.gov.
  STUDY NAME
Dose Escalation Study of Nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in Patients (Pts) With Advanced Hepatocellular Carcinoma (HCC) With or Without Chronic Viral Hepatitis
STUDY OVERVIEW
The purpose of this study is to evaluate the safety, pharmacokinetics, immunoregulatory activity, pharmacodynamics and preliminary anti-tumor activity of BMS-936558 in subjects with advanced hepatocellular carcinoma (HCC)
 

 
The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.
Find A Study